After a snow delay, ChemGenex will have more time to prepare for what may be a challenging review of Omapro (omacetaxine mepesuccinate) for chronic myeloid leukemia by FDA's Oncologic Drugs Advisory Committee.
During the BIO CEO & Investor conference, Merck Chief Licensing Officer Barbara Yanni says Merck is on the prowl for early-stage M&A opportunities and admits big pharma is becoming more open to outside sources for R&D.
